lamivudine | Zeffix tablets 100 mg, 28 pcs.
Special Price
$43.65
Regular Price
$52.00
In stock
SKU
BID464295
Release form
film-coated tablets.
film-coated tablets.
Release form
film-coated tablets.
Packing
28 pcs.
Pharmacological action
Antiviral drug - an analog of nucleosides.
Zeffix is highly active against hepatitis B.
In both infected and uninfected cells, lamivudine is metabolized to lamivudine triphosphate, which is an active form of the drug and serves as a substrate for hepatitis B virus DNA polymerase.
The incorporation of lamivudine triphosphate into the chain of viral DNA and subsequent chain termination block further viral DNA formation.
Lamivudine triphosphate does not interfere with normal cellular DNA metabolism.
It is also a weak inhibitor of mammalian - and -DNA polymerases. Lamivudine triphosphate does not significantly affect the DNA content in cells.
Indications
Chronic hepatitis B against the background of hepatitis B virus replication
Contraindications
Hypersensitivity to lamivudine or to any other Zeffix component, pregnancy (I trimester).
Caution should be used for renal failure, pancreatitis (including a history), peripheral neuropathy, pregnancy (II-III trimester), during lactation, in childhood (up to 2 years).
Special instructions
During treatment with Zeffix patients should be regularly monitored by a doctor who has experience in treating chronic hepatitis B.
Composition
1 table. contains lamivudine 100 mg.
Dosage and Administration
Zeffix is ??taken orally, regardless of food intake. Adults and children 12 years of age and older: 100 mg 1 time per day.
Side effects
The most common side effects are general malaise and fatigue, respiratory infections, headache, discomfort and abdominal pain, nausea, vomiting and diarrhea.
The frequency of changes in laboratory parameters in patients with chronic hepatitis B is similar with Zeffix and placebo, with the exception of a more frequent increase in ALT levels after completion of Zeffix therapy. However, a significant difference in the frequency of elevated ALT levels, combined with increased bilirubin levels and / or with signs of liver failure, is not detected. It is not known whether these cases of exacerbation of hepatitis are associated with treatment with Zeffix or with the peculiarities of the course of chronic hepatitis itself.
In patients with HIV infection, cases of the development of pancreatitis and peripheral neuropathy (or paresthesia) were observed, however, the relationship of these complications with lamivudine therapy has not been proven. There was no significant difference in the frequency of these complications in groups of patients with chronic hepatitis B who took Zeffix and placebo.
In patients with HIV infection who received combination therapy with nucleoside analogues, there were cases of lactic acidosis, which was usually accompanied by severe hepatomegaly and fatty liver. There are separate reports of the same side effects in patients with viral hepatitis B and liver failure, however, there is no data confirming the connection of these complications with Zeffix.
Overdose of
Symptoms: There are no specific symptoms of an overdose of lamivudine.
Recommended gastric lavage, the appointment of activated carbon, monitor the patient's condition and conduct standard maintenance therapy.
Continuous hemodialysis may be used to remove lamivudine, but no special studies have been conducted.
Storage Conditions
The product should be stored in a dry, dark place at a temperature not exceeding 20 РC.
Deystvuyuschee substances
lamivudine
Form of Treatment
tablets
indications Hepatitis
GlaxoSmithKline, UK
film-coated tablets.
Packing
28 pcs.
Pharmacological action
Antiviral drug - an analog of nucleosides.
Zeffix is highly active against hepatitis B.
In both infected and uninfected cells, lamivudine is metabolized to lamivudine triphosphate, which is an active form of the drug and serves as a substrate for hepatitis B virus DNA polymerase.
The incorporation of lamivudine triphosphate into the chain of viral DNA and subsequent chain termination block further viral DNA formation.
Lamivudine triphosphate does not interfere with normal cellular DNA metabolism.
It is also a weak inhibitor of mammalian - and -DNA polymerases. Lamivudine triphosphate does not significantly affect the DNA content in cells.
Indications
Chronic hepatitis B against the background of hepatitis B virus replication
Contraindications
Hypersensitivity to lamivudine or to any other Zeffix component, pregnancy (I trimester).
Caution should be used for renal failure, pancreatitis (including a history), peripheral neuropathy, pregnancy (II-III trimester), during lactation, in childhood (up to 2 years).
Special instructions
During treatment with Zeffix patients should be regularly monitored by a doctor who has experience in treating chronic hepatitis B.
Composition
1 table. contains lamivudine 100 mg.
Dosage and Administration
Zeffix is ??taken orally, regardless of food intake. Adults and children 12 years of age and older: 100 mg 1 time per day.
Side effects
The most common side effects are general malaise and fatigue, respiratory infections, headache, discomfort and abdominal pain, nausea, vomiting and diarrhea.
The frequency of changes in laboratory parameters in patients with chronic hepatitis B is similar with Zeffix and placebo, with the exception of a more frequent increase in ALT levels after completion of Zeffix therapy. However, a significant difference in the frequency of elevated ALT levels, combined with increased bilirubin levels and / or with signs of liver failure, is not detected. It is not known whether these cases of exacerbation of hepatitis are associated with treatment with Zeffix or with the peculiarities of the course of chronic hepatitis itself.
In patients with HIV infection, cases of the development of pancreatitis and peripheral neuropathy (or paresthesia) were observed, however, the relationship of these complications with lamivudine therapy has not been proven. There was no significant difference in the frequency of these complications in groups of patients with chronic hepatitis B who took Zeffix and placebo.
In patients with HIV infection who received combination therapy with nucleoside analogues, there were cases of lactic acidosis, which was usually accompanied by severe hepatomegaly and fatty liver. There are separate reports of the same side effects in patients with viral hepatitis B and liver failure, however, there is no data confirming the connection of these complications with Zeffix.
Overdose of
Symptoms: There are no specific symptoms of an overdose of lamivudine.
Recommended gastric lavage, the appointment of activated carbon, monitor the patient's condition and conduct standard maintenance therapy.
Continuous hemodialysis may be used to remove lamivudine, but no special studies have been conducted.
Storage Conditions
The product should be stored in a dry, dark place at a temperature not exceeding 20 РC.
Deystvuyuschee substances
lamivudine
Form of Treatment
tablets
indications Hepatitis
GlaxoSmithKline, UK
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review